Ensemble Therapeutics is teaming up with Roche’s Genentech to discover macrocyclic drug candidates against undisclosed protein targets. Genentech will have the right to develop and commercialise lead molecules arising from the collaboration. The partnership is Ensemble’s third with a major pharmaceutical company that leverages its Ensemblin™ discovery engine.